Welcome to TechVenture.news Startup Showcase, where we bring you the latest and most promising startups that are disrupting industries with groundbreaking innovations. In this edition, we present to you Inmagene Biopharmaceuticals, a leading biotech company based in Pudong, Shandong, China. With a focus on immunology-related therapeutic areas, Inmagene is revolutionizing the field of biopharmaceuticals with their advanced drug candidates and commitment to improving global healthcare.
Unleashing the Power of Immunology
Inmagene Biopharmaceuticals is at the forefront of the biotechnology industry, specializing in the development of novel therapeutics for immunology-related conditions. By leveraging cutting-edge research and technological advancements, Inmagene aims to address unmet medical needs and provide patients with improved treatment options.
IMG-020: Transforming Psoriasis and Psoriatic Arthritis Treatment
Among Inmagene’s impressive portfolio of drug candidates, IMG-020 (izokibep) stands out as their most advanced and promising development. This groundbreaking drug candidate has successfully met protocol endpoints in global phase II studies for both psoriasis and psoriatic arthritis (PsA). Such achievements demonstrate the immense potential of IMG-020 in transforming the lives of millions of patients suffering from these debilitating conditions.
Global Phase III Studies and Regulatory Approvals
Inmagene’s dedication to bringing their innovations to market is evident through the progress of IMG-020. The company has obtained IND (Investigational New Drug) approval from the China National Medical Products Administration’s Center for Drug Evaluation (CDE) for phase III studies in plaque psoriasis. This milestone paves the way for further advancements in treatment options for patients in China and beyond.
Collaborations for a Wider Impact
Recognizing the importance of collaboration, Inmagene is actively partnering with leading organizations to conduct global phase II trials for a range of autoimmune diseases. These collaborations include studies for psoriatic arthritis (PsA), ankylosing spondylitis (AS), and uveitis. By combining resources and expertise, Inmagene aims to accelerate the development of groundbreaking therapeutics, offering hope to patients worldwide.
IMG-004 and IMG-007: Expanding the Horizon
Inmagene’s dedication to innovation doesn’t stop with IMG-020. The company has two additional drug candidates, IMG-004 and IMG-007, both with global rights, currently in global phase I studies. These candidates hold tremendous promise and represent Inmagene’s commitment to expanding their pipeline of immunology-related therapeutics.
IMG-008: A Promising Future
Looking ahead, Inmagene is gearing up for another significant milestone with IMG-008, an internally developed drug candidate. Scheduled for global Investigational New Drug (IND) submission in 2022, IMG-008 has the potential to reshape the treatment landscape for immunology-related conditions. The company’s dedication to advancing novel therapeutics demonstrates their unwavering commitment to improving patient outcomes.Inmagene Biopharmaceuticals is leading the charge in revolutionizing immunology therapeutics. Their groundbreaking drug candidates and strategic collaborations promise a brighter future for patients worldwide. By leveraging the power of science and innovation, Inmagene is driving significant advancements in the field, creating a positive impact on global healthcare.
LinkedIn: https://www.linkedin.com/company/inmagene-biopharmaceuticals/
Website: http://www.inmagenebio.com/
